Vigil Neuroscience (VIGL)
(Real Time Quote from BATS)
$8.06 USD
+0.01 (0.12%)
Updated Aug 4, 2025 03:43 PM ET
After-Market: $8.08 +0.02 (0.25%) 4:06 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Vigil Neuroscience, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VIGL 8.06 +0.01(0.12%)
Will VIGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIGL
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?
VIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
Other News for VIGL
Catalyst Watch: Palantir earnings, Firefly Aerospace IPO, OPEC+, and the Fed's SLOOS report
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Tesla, Alphabet Set To Report Earnings As Investors Watch Out For Jobless Claims And Durable Goods Orders
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact